Disease Modeling & Screening Platform

Keyphrases

1. Alpha-synuclein (α-syn) 100%
2. A30P 99%
3. Patient-derived 99%
4. Parkinson's Disease 85%
5. Functional Profiling 82%
6. Patient-derived Spheroids 66%
7. C-X-C Chemokine Receptor Type 4 (CXCR4) 66%
8. Isogenic 66%
9. Human Immunodeficiency Virus Type 1 (HIV-1) 66%
10. Induced Pluripotent Stem Cells (iPSCs) 59%
11. Parkinson Patients 56%
12. C-C Chemokine Receptor Type 5 (CCR5) 44%
13. SNCA mutation 39%
14. Co-receptor 37%
15. Recombinant 37%
16. Idiopathic Parkinson's Disease 37%
17. Point mutation 37%
18. Personalized Drug Therapy 33%
19. Therapeutic Response 33%
20. Personalized Drug Screening 33%
21. Memory Impairment 33%
22. Post-COVID 33%
23. Metastatic Colorectal Cancer (mCRC) 33%
24. Topological Patterns 33%
25. Health Effects 33%
26. Viremic Controllers 33%
27. High-content Screening 33%
28. Heavy Chain 33%
29. Interaction Network 33%
30. Viral Infectivity 33%
31. Lung 33%
32. Neuronal Function 33%
33. Viral Assay 33%
34. Recurrent Glioblastoma 33%
35. Lipid Regulation 33%
36. Cytoplasmic Tail 33%
37. Complementarity-determining Region 3 (CDR3) 33%
38. Neuronal Branching 33%
39. Tropism 33%
40. Glioblastoma Organoids 33%
41. Mitochondria 33%
42. Patient-derived Organoids 33%
43. Prediction Algorithms 33%
44. Replication Capacity 33%
45. HIV-1 Subtype C 33%
46. Atypical Carcinoid 33%
47. Cell-to-cell Transmission 33%
48. CRF02_AG 33%
49. Tumor Profiling 33%
50. Functional Tumor 33%
51. Antiangiogenic Therapy 33%
52. Virion 33%
53. Synucleinopathy 33%
54. Geno2pheno 27%
55. CD4+ T 24%
56. Glioblastoma 24%
57. Targeted Therapy 24%
58. Liver Metastasis 24%
59. Drug Screening 23%
60. Drug Response 23%
61. Virus 21%
62. Complex Disease 20%
63. Individualized Treatment 16%
64. Treatment Choice 16%
65. Tumor Growth 16%
66. Patient Stratification 16%
67. Rapidly Evolving 16%
68. Enveloped Virus 16%
69. Personalized Medicine 16%
70. Oncology 16%
71. Infectivity 16%
72. Clinically Significant 16%
73. Tumor Progression 16%
74. Tumor Microenvironment 16%
75. Multiple System Atrophy 16%
76. Targeted Drugs 16%
77. Heterogeneous Disease 16%
78. Patient-specific 16%
79. Molecular Defects 16%
80. Isogenic Cell Lines 16%
81. Cell Phenotype 16%
82. Cancer Treatment 16%
83. Personalized Treatment 16%
84. Stratification Strategy 16%
85. Pleural Effusion 16%
86. Monocytes/macrophages 16%
87. Dopaminergic Neurons 16%
88. Patient-derived Cancer Model 16%
89. Objective Response 16%
90. Survival Improvement 16%
91. Drug Experience 16%
92. Tumor Development 16%
93. Precision Oncology 16%
94. Cancer Patients 16%
95. Patient Tumor 14%
96. Tumor 14%
97. Midbrain Dopaminergic Neurons 14%
98. Gp120 14%
99. Derived Peptide 14%
100. Vulnerability 13%